Blopress is an angiotensin II receptor blocker (ARB) and hydrochlorothiazide is classified as a thiazide diuretic and lowers the blood pressure by increasing the flow of urine, which results in volume depletion. It is considered that there is a synergistic anti-hypertensive effect by concominant therapy of ARB and diuretic.
Masaomi Miyamoto, general manager of pharmaceutical development division of Takeda, said: “We believe that the fixed dose combination tablet of Blopress with diuretic will be able to offer the better control of blood pressure. We expect that this new drug application (NDA) will lead to maximization of added value of Blopress.”